Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADEFOVIR DIPIVOXIL vs ATROPINE AND DEMEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.,Treatment of chronic hepatitis B in pediatric patients aged 12 years and older.
Preanesthetic medication to reduce secretions and prevent bradycardia,Management of moderate to severe pain (as an opioid analgesic),Off-label: treatment of opioid-induced constipation (meperidine component)
10 mg orally once daily on an empty stomach.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Adefovir dipivoxil is rapidly converted to adefovir by esterases. Adefovir is not significantly metabolized; it is eliminated renally by a combination of glomerular filtration and active tubular secretion. No CYP450-mediated metabolism.
Meperidine is primarily metabolized in the liver via hydrolysis to meperidinic acid and via N-demethylation to normeperidine (active metabolite), involving CYP3A4 and CYP2B6. Atropine is metabolized in the liver via hydrolysis and glucuronidation; approximately 50% is excreted unchanged in urine.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
≤4% (low binding; negligible affinity for serum proteins)
Atropine: ~44% bound to albumin and alpha-1 acid glycoprotein. Demerol: ~60% bound to albumin and alpha-1 acid glycoprotein.
0.4 L/kg (392 L in adults); indicates extensive tissue distribution (including liver).
Atropine: 1-3 L/kg (large, extensive tissue distribution). Demerol: 3-5 L/kg (large, distributes widely including CNS).
Oral: 59% (range 40–70%); prodrug adefovir dipivoxil is rapidly converted to adefovir.
Atropine: oral ~10-25% (extensive first-pass metabolism). Demerol: oral ~50-60% (significant first-pass metabolism). IM/IV 100%.
Cr Cl ≥50 m L/min: 10 mg every 24 hours; Cr Cl 30-49 m L/min: 10 mg every 48 hours; Cr Cl 10-29 m L/min: 10 mg every 72 hours; Hemodialysis: 10 mg every 7 days after dialysis.
Meperidine: GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose and avoid due to normeperidine accumulation. Atropine: no adjustment required.
No adjustment required for mild-moderate hepatic impairment (Child-Pugh A or B). Not studied in severe (Child-Pugh C).
Meperidine: Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce by 50%; Child-Pugh C: contraindicated. Atropine: caution in severe hepatic impairment.
Approved for age ≥12 years: 10 mg orally once daily. For age <12 years, use is not established.
Atropine 0.01 mg/kg (max 0.4 mg) and meperidine 1-2 mg/kg (max 100 mg) intramuscularly 30-60 minutes before procedure.
Monitor renal function; adjust dose based on Cr Cl. No specific dose adjustment solely for age.
Reduce meperidine dose by 50% and avoid in elderly due to risk of seizures and delirium; use alternative opioids. Atropine dose unchanged but monitor for anticholinergic effects.
WARNING: SEVERE ACUTE EXACERBATION OF HEPATITIS B, NEPHROTOXICITY, HIV RESISTANCE, and LACTIC ACIDOSIS/HEPATOMEGALY WITH STEATOSIS. See full prescribing information for complete boxed warning.
Meperidine has a boxed warning for risk of respiratory depression, especially in elderly, cachectic, or debilitated patients, and when used with CNS depressants. Also, risk of serotonin syndrome when co-administered with serotonergic drugs, and risk of abuse, addiction, and diversion.
Severe acute exacerbation of hepatitis B upon discontinuation of therapy,Nephrotoxicity: monitor renal function, especially in patients at risk or with pre-existing renal impairment,HIV resistance: test for HIV before initiation in patients with unknown HIV status,Lactic acidosis and severe hepatomegaly with steatosis,Use with caution in elderly, renal impairment, or concomitant nephrotoxic agents
Respiratory depression, hypotension, bradycardia, urinary retention, constipation, serotonin syndrome, seizures (normeperidine accumulation), decreased GI motility, drug dependence, and tolerance. Use caution in elderly, renal impairment, hepatic impairment, respiratory disorders, prostatic hyperplasia, glaucoma, and with concurrent CNS depressants.
Hypersensitivity to adefovir dipivoxil or any component of the formulation
Hypersensitivity to atropine or meperidine; severe asthma or COPD; acute respiratory depression; paralytic ileus; known or suspected gastrointestinal obstruction; patients receiving MAOIs (within 14 days); myasthenia gravis (relative for atropine); increased intraocular pressure (glaucoma); severe renal impairment (normeperidine accumulation).
No clinically significant food interactions; can be taken with or without food. Avoid high-fat meals if gastrointestinal intolerance occurs.
Avoid alcohol. Meperidine may interact with foods containing tyramine (aged cheeses, cured meats) in patients on MAOIs; otherwise no significant food interactions.
Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. In first trimester, risk cannot be excluded; use only if benefit outweighs risk. In second and third trimesters, potential for fetal harm exists; consider alternative therapy.
Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studies show no teratogenicity. Second trimester: no specific risks. Third trimester: use near term may cause neonatal respiratory depression, decreased Apgar scores, and withdrawal symptoms. Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS).
It is unknown whether adefovir is excreted in human breast milk. Animal studies indicate it is present in rat milk. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy or for 2 weeks after last dose.
Atropine: Excreted in breast milk in small amounts; may inhibit lactation. M/P ratio not established. Use with caution; monitor infant for anticholinergic effects (tachycardia, dry mouth). Demerol: Excreted in breast milk; relative infant dose (RID) ~0.5-0.8% of maternal weight-adjusted dose. M/P ratio 1.0-1.6. Limited data; avoid in breastfeeding due to potential neonatal sedation and respiratory depression. American Academy of Pediatrics considers meperidine compatible but caution advised.
Pregnancy may increase renal clearance; however, specific pharmacokinetic data are lacking. Dose adjustment is not routinely recommended but may be necessary if renal function changes. Use standard dose of 10 mg once daily with monitoring of renal function and HBV DNA levels.
Atropine: No specific dose adjustments recommended; increased volume of distribution may require higher doses for effect. Demerol: Increased clearance and volume of distribution in pregnancy; standard doses may be less effective. Avoid use during labor due to risk of neonatal respiratory depression; if necessary, use lowest effective dose and monitor neonate. No specific dose reduction recommended, but caution with repeated doses.
Monitor renal function closely; dose adjust for Cr Cl <50 m L/min. Check LFTs and HBV DNA every 3 months. Avoid in decompensated cirrhosis. HIV co-infected patients require concomitant antiretroviral therapy due to risk of HIV resistance. Prolonged therapy may lead to adefovir-resistant HBV mutations (rt A181V/T, rt N236T).
Atropine and Demerol (meperidine) combination is used for pre-anesthetic medication to reduce secretions and produce sedation. Monitor for CNS depression, respiratory depression, and anticholinergic effects (tachycardia, dry mouth, urinary retention). Use cautiously in elderly, patients with COPD, asthma, or prostatic hyperplasia. Avoid in patients with MAOIs due to risk of serotonin syndrome.
Take with or without food at the same time daily.,Do not stop taking without consulting your doctor; stopping may cause severe hepatitis flare.,Report any signs of kidney problems (decreased urination, swelling) or lactic acidosis (unusual muscle pain, trouble breathing).,Regular blood tests are required to monitor liver and kidney function.,Use effective contraception during treatment if you or your partner can become pregnant.,Avoid alcohol and other medications that can damage the liver or kidneys without medical advice.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until effects are known.,Avoid alcohol and other CNS depressants while taking this medication.,Report difficulty urinating, fast heartbeat, or severe constipation to your healthcare provider.,Do not take more than prescribed; risk of dependence with long-term use.,Keep out of reach of children; may cause serious breathing problems if accidentally taken.
"Coadministration of adefovir dipivoxil and tenofovir disoproxil may reduce the antiviral efficacy of tenofovir by competing for renal tubular secretion via organic anion transporters (OATs) and potentially intracellular phosphorylation pathways. This competition can decrease tenofovir's intracellular active metabolite concentrations, leading to suboptimal viral suppression and increased risk of treatment failure in patients with chronic hepatitis B."
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
"Rivastigmine, a reversible carbamate acetylcholinesterase inhibitor, increases synaptic acetylcholine levels, enhancing cholinergic transmission. Atropine, a competitive antagonist of muscarinic acetylcholine receptors, blocks the effects of acetylcholine at these receptors, leading to reduced parasympathetic activity. When used together, atropine can diminish the therapeutic efficacy of rivastigmine by pharmacodynamically antagonizing its cholinergic effects, particularly in the central nervous system and peripheral muscarinic receptors, potentially worsening cognitive function in Alzheimer's disease patients."
"Umeclidinium, a long-acting muscarinic antagonist (LAMA), and atropine, a non-selective muscarinic antagonist, both block the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. Their co-administration leads to additive anticholinergic effects, resulting in an increased risk of peripheral anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and tachycardia, as well as central nervous system effects like confusion or delirium, especially in elderly patients. Clinically, this combination may also exacerbate conditions such as angle-closure glaucoma or paralytic ileus."
"Concurrent use of atropine and gallamine triethiodide results in additive antagonism at muscarinic acetylcholine receptors, leading to enhanced blockade of parasympathetic effects and increased risk of tachycardia, hypertension, and delirium. Atropine, a competitive antagonist of muscarinic receptors, counteracts the vagolytic effects of gallamine, a nondepolarizing neuromuscular blocker that also exhibits weak vagolytic activity. This pharmacodynamic interaction can cause severe sinus tachycardia, hypertension, and central anticholinergic syndrome, especially in elderly patients or those with cardiovascular disease."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADEFOVIR DIPIVOXIL vs ATROPINE AND DEMEROL, answered by our medical review team.
ADEFOVIR DIPIVOXIL is a Antiviral that works by Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.. ATROPINE AND DEMEROL is a Opioid Analgesic Combination that works by Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADEFOVIR DIPIVOXIL and ATROPINE AND DEMEROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADEFOVIR DIPIVOXIL is: 10 mg orally once daily on an empty stomach.. The standard adult dose of ATROPINE AND DEMEROL is: Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADEFOVIR DIPIVOXIL and ATROPINE AND DEMEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADEFOVIR DIPIVOXIL is classified as Category C. Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. ATROPINE AND DEMEROL is classified as Category C. Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.